Evidence map›Paper›PMID 28671484›Full record

ArticlePulmonary circulation

Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH): A Delphi consensus document.

Franck F Rahaghi, Hassan M Alnuaimat, Rana L A Awdish, Vijay P Balasubramanian, Robert C Bourge, Charles D Burger, John Butler, C Gregory Cauthen, Murali M Chakinala, Bennett P deBoisblanc and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pulmonary circulation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. International Society for Heart and Lung Transplantation Scientific Statement on pulmonary antibody-mediated rejection and proposed graft, antibody, and pathology (GAP) definition.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2026
    Guideline
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis.European respiratory review : an official journal of the European Respiratory Society · 2020
    Review
  9. Management of repository corticotrophin injection therapy for pulmonary sarcoidosis: a Delphi study.European respiratory review : an official journal of the European Respiratory Society · 2020
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Franck F Rahaghi1 Cleveland Clinic Florida, Weston, FL, USA.
Hassan M Alnuaimat2 Shands Hospital, University of Florida, Gainesville, FL, USA.
Rana L A Awdish3 Henry Ford Hospital, Detroit, MI, USA.
Vijay P Balasubramanian4 UCSF Fresno, Fresno CA, USA.
Robert C Bourge5 The University of Alabama at Birmingham, Birmingham, AL, USA.ORCID http://orcid.org/0000-0001-9035-4133
Charles D Burger6 Mayo Clinic, Jacksonville, FL, USA.
John Butler7 The Oregon Clinic, Portland, OR, USA.
C Gregory Cauthen8 Providence Hospitals, Columbia, SC, USA.
Murali M Chakinala9 Washington University School of Medicine, St Louis, MO, USA.
Bennett P deBoisblanc10 Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Michael S Eggert11 Sentara Heart Hospital, Norfolk, VA, USA.
Peter Engel12 Ohio Heart & Vascular Center; The Christ Hospital, Cincinnati OH, USA.
Jeremy Feldman13 Arizona Pulmonary Specialists, Phoenix, AZ, USA.
J Wesley McConnell14 University of Kentucky, Louisville, KY, USA.
Myung Park15 Houston Methodist Hospital, Houston, TX, USA.
Jeffrey S Sager16 Cottage Pulmonary Hypertension Center, Santa Barbara, CA, USA.
Namita Sood17 Ohio State University, Columbus, OH, USA.
Harold I Palevsky18 University of Pennsylvania, Philadelphia, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In patients treated with macitentan (Opsumit®, Actelion Pharmaceuticals Ltd., Basel, Switzerland) for pulmonary arterial hypertension (PAH), prevention and/or effective management of treatment-related adverse events may improve adherence. However, management of these adverse events can be challenging and the base of evidence and clinical experience for macitentan is limited. In the absence of evidence, consensus recommendations from physicians experienced in using macitentan to treat PAH may benefit patients and physicians who are using macitentan. Consensus recommendations were developed by a panel of physicians experienced with macitentan and PAH using a modified Delphi process. Over three iterations, panelists developed and refined a series of statements on the use of macitentan in PAH and rated their agreement with each statement on a Likert scale. The panel of 18 physicians participated and developed a total of 118 statements on special populations, add-on therapy, drug-drug interactions, warnings and precautions, hospitalization and functional class, and adverse event management. The resulting consensus recommendations are intended to provide practical guidance on real-world issues in using macitentan to treat patients with PAH.

Indexed as

adverse eventsendothelin receptor antagonisttherapy adherence

Identifiers

PMID28671484
PMCPMC5841904

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.